All News

DLE discoid lupus

A Pilot Trial of Anifrolumab in Discoid Lupus

Jack Cush, MD

A research report in JAMA Dermatology describes the use of the type 1 interferon receptor inhibitor anifrolumab in patients with chronic discoid lupus erythematosus (DLE). 

Read Article
immune.activity.cytokine.jpg

Itaconate - A Potential New Immunosuppressive

EurekAlert!

Researchers have revealed the modulatory effect of the anti-inflammatory metabolite itaconate (ITA) on T helper and T regulatory cells, which may lead to new therapeutic approaches to treating some autoimmune diseases.

Read Article
RheumNow Podcast square

Big Time Vasculitis (3.10.2023)

Jack Cush, MD

Dr. Jack Cush Reviews the News and Journal articles from the past week on RheumNow. This weeks highlights includes insights on scleroderma, myositis, vasculitis and answers the question - does aggressive biologic treatment of psoriasis prevent future psoriatic arthritis?

Read Article
sclerodact.jpg

Long-Term Benefit of Rituximab in Systemic Sclerosis

Jack Cush, MD

A small cohort trial of rituximab (RTX) in 29 systemic sclerosis patients showed significantly improved skin sclerosis and lung function after a follow-up of 96 weeks.

Read Article
ANCA.jpg

Renal Involvement is Pivotal in ANCA-Associated Vasculitis

MedPage Today

Bearing in mind that renal impairment is among the worst complications of ANCA-associated vasculitis (AAV), researchers have identified four different trajectories of kidney function over time in AAV patients, with implications for personalized treatment, as well as future research.

Read Article
RheumNow Podcast square

NSAIDs in Pregnancy (3.3.2023)

Jack Cush, MD

Dr. Jack Cush reviews the lastest journal articles, news, and FDA announcements from the past week on RheumNow.  This week, the importance of IFNa, Subclinical PsA and NSAID safety during Pregnancy.

Read Article
colitis.jpg

VEGA - The Efficacy of Combination Biologics in Ulcerative Colitis

Jack Cush, MD

A novel trial has shown that combination biologic therapy (guselkumab plus golimumab) to be more effective in ulcerative colitis than either biologic alone.

Read Article
Was amazed at the tons of biosimilar TNF options @_connectedcare uses in Australia... coming soon to the US! Jonathan Kay #RNL2022 shows the lists of biosimilar May be w/in batch-to-batch variability, unintended drift, or deliberate process changes (evolution) @RheumNow https://t.co/sfVQspxbyr
Eric Dein ericdeinmd ( View Tweet)
Jonathan Kay on #RNL2023: Biosimilar is well-researched with cost savings These savings should benefit the patients Incentives for physicians as well in form of decreased prior auth burdens @RheumNow

Eric Dein ericdeinmd ( View Tweet)

Do you stop MTX on patients on bDMARD? MTX decrease anti-drug antibodies on patients on infliximab - increases drug duration. Similar seen with new combination usage with pelogloticase Joel Kremer MD #RhuemNow @RheumNow https://t.co/8UrGZaFStA
Eric Dein ericdeinmd ( View Tweet)
Dr. Langford #RNL2023 When to use CYC over RTX for severe GPA induction? - Severe disease with RTX intolerance - Worsening disease despite RTX - RGPN Cr > 4.0, mechanical ventilation? (these were excluded from RAVE trial) @RheumNow https://t.co/twVJ81pgUK
Eric Dein ericdeinmd ( View Tweet)
Sirilumab ( SAPHYR trial) in PMR, By Dr.Robert Spiera #RNL2023 ⁦@RheumNow⁩ It also improved patient reported outcomes. Great news👌 https://t.co/NDxhIwvACq
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
Itaconate - A Potential New Immunosuppressive Researchers have revealed the modulatory effect of the anti-inflammatory metabolite ITA on T helper and T regulatory cells, which may lead to new therapeutic approaches to treating some autoimmune diseases. https://t.co/1kaxHou8pz https://t.co/VLLAzgiYoM

Links:

Dr. John Cush RheumNow ( View Tweet)
Cost-Effective Use of Biological and Targeted Synthetic DMARDs An international task force of experts have developed evidence-based points to consider regarding the cost-effective use of b/tsDMARDs in the treatment of inflammatory rheumatic diseases. https://t.co/jpxQggd89T https://t.co/zjer5QTN3C

Links:

Dr. John Cush RheumNow ( View Tweet)
Does Biologic Treatment in Psoriasis Reduce the Risk of PsA? Retrospective claims analysis shows that psoriasis patients treated with an IL-12/23 inhibitor or an IL-23 inhibitor had a lower risk of developing incident PsA. https://t.co/j73V7zMnkn https://t.co/EhGUXDNNlS

Links:

Dr. John Cush RheumNow ( View Tweet)
Systemic sclerosis current therapy: - early dcSSc: MMF, CTX, RTX, TCZ - rapidly progressive dcSSc - ?Stem cell transpl? - SSc-ILD: MMF>CTX, possibly nintedanib, perfinidone - Raynauds w/ digital ulcers: CA channel block, PDE5 inhib, iloprost, Bosentan https://t.co/87giuQR4YZ https://t.co/z2TPlJnu5e

Links:

Dr. John Cush RheumNow ( View Tweet)
Long-Term Benefit of Rituximab in Systemic Sclerosis A small cohort trial of rituximab (RTX) in 29 systemic sclerosis patients showed significantly improved skin sclerosis and lung function after a follow-up of 96 weeks. https://t.co/f68wc6lQGH https://t.co/G4PKPnJ0LJ

Links:

Dr. John Cush RheumNow ( View Tweet)
2017 Prevalence of Psoriatic arthritis (PsA) in Sweden estimated to be 0.34% (range 0.32-0.50% across all sensitivity analyses); lower in males & w/ higher level of education. 0.24% have seen rheumatology care- 32% on b/ts-DMARDs, 41% csDMARDs https://t.co/Jh2WUYVJR2 https://t.co/ZdFVIq2iQ0

Links:

Dr. John Cush RheumNow ( View Tweet)
Study of 197 AAV pts in RAVE trial (RTX vs CTX; followed by AZA) showed most serious infections (82%) occurred in 6 mos (68% Resp infx) & assoc w/ lower#s CD19+ cells. TMP/SMX prophylaxis against P. jirovecii decreased SIE rates https://t.co/oz530OkGs8 https://t.co/YFW7PD6wrW

Links:

Dr. John Cush RheumNow ( View Tweet)
FDA has approved sarilumab (Kevzara) for the treatment of polymyalgia rheumatica (PMR) in adult patients who have had an inadequate response to corticosteroids or who cannot tolerate corticosteroid taper. Approval is based on Phase 3 SAPHYR study https://t.co/7GHG2uG9yQ https://t.co/MZ7RYGdDfG

Links:

Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×